The patent landscape for pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), is characterized by groundbreaking discoveries, legal challenges, and debates over accessibility. The patent environment surrounding these stem cell types is complicated, and there are a number of restrictions on how the cells can be used for commercial and strategic purposes.
Embryonic Stem Cells and WARF Patents
The most infamous stem cell patents are held by the Wisconsin Alumni Research Foundation (WARF) and concern the derivation of human embryonic stem cells (hESCs). Founded in 1925, the WARF is a nonprofit patent and licensing organization for the University of Wisconsin–Madison.” It manages a $2.6 billion endowment build over 90 years of licensing activity , making it one of the world’s most successful university-based technology transfer offices.
In 2006, Jeanne Loring of Scripps Research Institute and two public interest groups, Consumer Watchdog and the Public Patent Foundation, challenged the WARF patents. Due to the controversial nature of the court case, the WARF patent dispute grew into one of the best known patent disputes within the stem cell sector. Although it was settled in U.S. courts between 2008 and 2010[1], appeals continued through February of 2015[2]. In February of 2015, the prolonged court case ended with the U.S. Supreme Court deciding not hear any further appeals. The decision meant that WARF was allowed to keep its patent rights concerning embryonic stem cell (ESC) derivation, based on the discovery of the cell type by James Thompson in 1998.
Nonetheless, the challengers succeeded in preventing WARF from gaining rights over induced pluripotent stem cells (iPSCs), which would have given WARF nearly impenetrable control over pluripotent stem cell types.[3]
iPSCs and the Yamanaka Patent
In 2006, Drs. Yamanaka and Takahashi filed a U.S. patent claiming a method for creating iPSCs titled “Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells,” which was issued as U.S. Patent No. 8,058,065 to Kyoto University on November 15, 2011. While there have been other patents issued pertaining to the cellular reprogramming and creation of iPSCs, this patent is the dominant one within the iPSC sector and the one limiting commercial development of iPSC products.
The Abstract for U.S. Patent Number 8,058,065 reads:
“Induced pluripotent stem cells are produced from human somatic cells by co-culturing human somatic cells having a reprogrammed nucleus with human cells as feeder cells. Induced pluripotent stem cells are produced from somatic cells by co-culturing somatic cells having a reprogrammed nucleus with autologous cells as feeder cells. Induced pluripotent stem cells are cultured with culture supernatant of somatic cells.”
Often called the “Yamanaka Patent,” this famous patent is was challenged in 2014 by a group called BioGatekeeper, Inc. If the “Yamanaka Patent” challenge had been successful, it could have spurred incredible innovation within the stem cell sector by allowing for lower cost creation of iPSC products, technologies, and therapies. Currently, most companies are forced to pay licensing fees to use the methodology described in the “Yamanaka Patent,” fees which are often prohibitively expensive.
However, the dispute did not last long, as the United States Patent and Trademark Office (USPTO) before the Patent Trial and Appeal Board dismissed the case on February 11, 2015, stating:
“The Petition does not persuade us that there is a reasonable likelihood that the challenged claim 1 is unpatentable based on the asserted ground. We decline to institute an inter parts review of claim 1 under 35 U.S.C. § 103(a) as obvious over the combination of Jaenisch, Benvenisty, and Li. 37 C.F.R. § 42.108(c).”
Impact on Innovation
The dominance of these patents has fueled debates about the trade-off between protecting intellectual property and fostering innovation. High licensing fees tied to the Yamanaka Patent, for instance, pose barriers for many organizations, potentially limiting the development of new iPSC-based therapies and products.
While ESC patents remain crucial, the inability of WARF to secure rights over iPSCs highlights the evolving nature of intellectual property as technology advances and the need for balancing innovation with accessibility.
Also, a 2024 analysis of over 11,000 iPSC-related patents shows that the U.S., Japan, and China are leaders in this field, with Kyoto University holding the most patents. The research focus has shifted toward improving safety and efficiency, such as non-viral reprogramming methods, to expand clinical applications. The rise of corporate-held patents reflects increasing industrial interest in iPSC commercialization.
These intertwined legal battles and advancements underscore the high stakes of stem cell research, highlighting the critical role of patents in shaping the pace and accessibility of innovation in regenerative medicine.
What questions do you have about ESC and iPSC patent positions? Ask them in comments below.